Seth Braunstein, MD
Endocrinology, Diabetes & Metabolism · Wilmington, NCNPI 1427080720
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,059 of the $133,680 with a category attached, or 77.1%. 56 manufacturers reported payments, led by Novo Nordisk at 57.8% of the total. Reporting peaked in 2019 at $86,019 and has fallen 96.8% since, to $2,768 in 2025.
Across 979 payments — averaging $136.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$77K
- Amarin Pharma, Inc.$42K
- Johnson & Johnson$3K
- Lilly USA, LLC$2K
- Boehringer Ingelheim$1K
- Abbott$991
- plus $8K from 50 others
What the payments were for
- Speaking & faculty fees$103,05977%
- Travel & lodging$14,47111%
- Food & beverage$15,95512%
- Education$1950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,680 in reported general payments places this provider in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 405 | $500,484 |
| MounjaroTirzepatide | 360 | $422,144 |
| JardianceEmpagliflozin | 369 | $421,636 |
| TrulicityDulaglutide | 98 | $136,900 |
| FarxigaDapagliflozin Propanediol | 93 | $108,198 |
| Tresiba Flextouch U-200Insulin Degludec | 66 | $97,880 |
| Tresiba Flextouch U-100Insulin Degludec | 105 | $77,578 |
| JanuviaSitagliptin Phosphate | 63 | $71,374 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 372 | $61,365 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 49 | $61,134 |
| Novolog FlexpenInsulin Aspart | 209 | $56,067 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 80 | $51,844 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $48,042 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 42 | $38,364 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $37,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Rybelsus, Fiasp | $77,251 | $578,846521 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev | $1,737 | $575,134472 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,097 | $455,500395 claims |
| AstraZenecaFarxiga | $567 | $108,19893 claims |
| MerckJanuvia, Janumet, Janumet Xr | $157 | $87,94286 claims |
| Johnson & JohnsonInvokana | $3,040 | $37,10329 claims |
| Radius Health, Inc.Tymlos | $294 | $29,42511 claims |
| Sanofi-aventis U.S. LLCLantus | $764 | $14,53351 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Wilmington
- Michael FavoritoWilmington$723K
- John ParkerWilmington$225K
- Lauren GratianWilmington$34K
- Sean McCalmonWilmington$10K
- Michael McGarrityWilmington$9K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.